Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881606 | 1.00 | MCHR1 (0.50) | MCHR1ACHEBCHEBACE1GRM2 | |
| SCHEMBL2876352 | 0.92 | MCHR1 (0.41) | MCHR1ACHEBCHEBACE1HRH3 | |
| SCHEMBL2876354 | 0.92 | MCHR1 (0.41) | MCHR1ACHEBCHEBACE1HRH3 | |
| SCHEMBL2876395 | 0.91 | MCHR1 (0.42) | MCHR1ACHEBCHEBACE1HRH3 | |
| SCHEMBL2876393 | 0.91 | MCHR1 (0.42) | MCHR1ACHEBCHEBACE1HRH3 | |
| SCHEMBL2881131 | 0.72 | MCHR1 (0.67) | MCHR1KCNH2 | |
| SCHEMBL2881734 | 0.72 | MCHR1 (0.67) | MCHR1KCNH2 | |
| SCHEMBL2881135 | 0.72 | MCHR1 (0.67) | MCHR1KCNH2 | |
| SCHEMBL2881733 | 0.72 | MCHR1 (0.67) | MCHR1KCNH2 | |
| SCHEMBL2886910 | 0.71 | MCHR1 (0.56) | MCHR1HRH3HTR7HTR6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216758-A1 | Pyridone Compounds | MSD K.K. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-1916239-A1 | PYRIDONE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216758-A1 | Pyridone Compounds | NPY1R, MC5R, MC1R | MCHR1 4/4885ACHE 3052/4885BCHE 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.